Skip to main content
OpenTrials
Completed

NCT Number: NCT05553080

Significance of Immunohistochemical Expression of Fascin-1 in Colorectal Carcinoma

Colorectal carcinoma is a major health problem. As a malignant tumor, the malignant potential of colorectal carcinoma is based mainly on its ability to metastasis to different sites. Fascin-1 is an actin binding protein which is involved in reconstruction of intracellular actin network, the latter enforces the neoplastic cell to invade surrounding structures.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Maisa Hashem Mohammed, Sohag, Egypt

Loading trial locations.

About this study

colorectal carcinoma is an aggressive malignant tumor. It has high incidence of cancer-related morbidity and mortality. the malignant potential of a given neoplasm is based mainly on its ability to invade the surrounding vasculature and reach to distant sites, the latter is called metastasis. in order to metastasize to distant sites, the neoplastic cells must re-arrange the intracellular actin filaments into well formed intracellular assembly which enable the neoplastic cells to reach to distant sites. Fascin-1 is an actin binding protein, it is involved in reconstruction of actin assembly. fortunately, Fascin-1 could be blocked by newly developed medications, blocking of Fascin-1 may limit the metastasis of colorectal carcinoma. in current study the investigators detect Fascin-1 in colorectal carcinoma by immunohistochemical approach, then they correlated different levels of Fascin-1 expression to tumor clinical and pathological criteria as patients' ages, sexes, tumor stages, nodal metastasis, vascular and per-ineural invasions.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All cases of colorectal carcinoma.

Exclusion criteria

  • cases diagnosed on basis of lower endoscopic biopsies or local resections without radical colectomy.
  • Patients with preopoerative history of chemo or radiotherapy.
  • Patients with poor clinical data.

Treatment and study plan

Immunohistochemistry

Genetic

immunohistochemical staining of colorectal carcinoma specimens by anti human fascin antibody.

Primary outcomes

  1. Evaluation of immunohistochemical staining of colorectal carcinoma by Fascin-1

    Time frame: September , 2022

    correlation of different levels of Fascin-1 expression to patients' ages, sexes, tumor stage, nodal metastasis, vascular and perineural invasion.

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Sep 23, 2022
Registry last updated
Apr 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.